Capital Advisors Ltd’s Nautilus Biotechnolgy NAUT Stock Holding History

Capital Advisors Ltd’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-186	Closed	–	–	1486
2022 Q3	$0	Buy	+186	New	+$468	﹤0.01%	1416

Other funds holding NAUT

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return

ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return

Capital Advisors Ltd's NAUT Position: Q4 2022 in Review

Capital Advisors Ltd sold out of Nautilus Biotechnolgy (NAUT) in Q4 2022, closing a stake of 186 shares.

Capital Advisors Ltd first reported a position in NAUT in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 81 funds tracked by Wall St. Rank hold NAUT as of Q4 2022.

Capital Advisors Ltd reported no remaining Nautilus Biotechnolgy position as of Q4 2022 after selling out during the quarter.
Capital Advisors Ltd sold 186 Nautilus Biotechnolgy shares in Q4 2022.
Capital Advisors Ltd first reported a position in Nautilus Biotechnolgy in Q3 2022 and held it in 1 quarter.
Capital Advisors Ltd's Nautilus Biotechnolgy position peaked at $0 in Q3 2022.
81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.